查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600450

抗血小板药物市场：按药物类型、剂型、适应症、作用机制、给药方法、分销管道和最终用户分类 - 2025-2030 年全球预测

Antiplatelet Market by Drug Type (Abciximab, Aspirin, Clopidogrel), Drug Formulation (Capsule, Injection, Tablet), Indication, Mechanism of Action, Mode of Administration, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗血小板药物市值为39.3亿美元，预计到2024年将达到41.9亿美元，复合年增长率为6.67%，到2030年将达到61.9亿美元。

抗血小板药物是重要的治疗药物，用于预防血小板凝集，从而降低中风和心肌梗塞等血栓事件的风险。由于人口老化、饮食习惯和久坐的生活方式导致世界各地心血管疾病的发病率不断上升，更加强调了对此类药物的需求。这些药物主要用于治疗急性冠状动脉症候群、经经皮冠状动脉介入治疗后以及预防缺血性中风。最终用途主要包括医院、诊所和门诊手术中心，这表明医疗基础设施发达的地区和正在经历快速医疗整合的新兴市场有很高的需求。该市场的关键成长要素包括心血管疾病负担的增加、意识和诊断率的提高以及疗效和安全性提高的新药的开发。引入个人化医疗方法和持续开发改善临床结果的联合治疗存在重大商机。

主要市场统计
基准年[2023] 39.3亿美元
预测年份 [2024] 41.9亿美元
预测年份 [2030] 61.9亿美元
复合年增长率（%） 6.67%

儘管具有潜力，抗血小板药物市场仍面临一些限制和挑战。严格的监管要求、潜在的副作用和先进疗法的高成本可能会阻碍市场成长。此外，抗凝血剂等替代疗法的可用性也可能影响抗血小板药物的采用。然而，创新的研究领域，例如开发新的药物输送系统和改进副作用较少的配方，提供了巨大的业务成长机会。对精准医疗和生物技术进行个人化治疗的投资也至关重要。同时，了解竞争动态，例如製药公司之间的整合趋势和研发策略联盟，对于市场渗透和扩张至关重要。准确关注应对这些挑战、与监管环境保持一致并利用技术进步对于了解抗血小板药物市场的未来前景至关重要。

市场动态：揭示快速发展的抗血小板药物市场的关键市场洞察

供需的动态交互作用正在改变抗血小板药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球心血管疾病盛行率不断上升
    • 政府对医药产业的投资支持
  • 市场限制因素
    • 抗血小板药物回收数量增加
    • 与抗血小板药物相关的副作用和出血风险
  • 市场机会
    • 个人化医疗抗血小板药物治疗方法的发展趋势日益明显
    • 新抗血小板疗法的广泛研发和临床试验
  • 市场挑战
    • 严格的监管要求和漫长的新药认证流程

波特五力：驾驭抗血小板药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗血小板药物市场的外部影响

外部宏观环境因素在塑造抗血小板药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗血小板药物市场竞争状况

抗血小板药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗血小板药物市场供应商绩效评估

FPNV定位矩阵是评估抗血小板药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘抗血小板药物市场的成功之路

抗血小板药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球心血管疾病盛行率不断上升
      • 政府对医药产业的支持性投资
    • 抑制因素
      • 抗血小板药物的产品召回数量正在增加。
      • 与抗血小板药物相关的副作用和出血风险
    • 机会
      • 个人化医疗开发个人化治疗方法的趋势不断增长
      • 抗血小板新药的广泛研发与临床试验
    • 任务
      • 新药监管要求严格、核准流程漫长
  • 市场区隔分析
    • 药物处方：扩大抗血小板药物注射剂的使用
    • 药物类型：阿昔单抗广泛用于高风险心血管干预
    • 作用机转：COX抑制剂的使用迅速增加以抑制闭塞
    • 适应症：对抗血小板药物的需求不断增加，以解决心血管疾病盛行率上升的问题
    • 给药方式：口服抗血小板药物正在增加
    • 最终用户：门诊手术中心抗血小板药物的需求不断增加
    • 分销管道：增加直接接触病患的医院药房的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按类型分類的抗血小板药物市场

  • 阿昔单抗
  • 阿斯匹灵
  • Clopidogrel
  • 双嘧达莫
  • 普拉格雷
  • 奇卡古雷勒
  • 噻氯匹定
  • 替罗非班

第七章依处方分类的抗血小板药物市场

  • 胶囊
  • 注射
  • 锭剂

第八章按适应症分類的抗血小板药物市场

  • 冠状动脉疾病
  • 周边动脉疾病
  • 中风
    • 出血性的
    • 缺血性的

第九章依作用机转分類的抗血小板药物市场

  • 环氧化酶抑制剂
  • P2Y12抑制剂
  • 磷酸二酯酶抑制剂

第十章按管理方式分類的抗血小板药物市场

  • 静脉
  • 口服

第十一章抗血小板药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十二章抗血小板药物市场：依最终用户分类

  • 门诊手术中心
  • 诊所
  • 家庭护理设置
  • 医院

第十三章美洲抗血小板药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第14章亚太地区抗血小板药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章 欧洲、中东和非洲抗血小板药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 根据 FDA 回馈，Diapin Therapeutics 正在开发创新抗血小板疗法 DT678
    • FDA 迅速核准Bentracimab 作为替格瑞洛拮抗剂的突破性疗法
    • Usea 美国召回了 15,500管瓶单剂量依替巴肽注射。
    • Avenacy 进入美国市场，推出针对 ACS 和 PCI 治疗的非专利药依替巴肽注射液
    • UCHealth 正在开创Clopidogrel基因检测的先河，以改善心臟健康并彻底改变个人化医疗。
    • Ascendia Pharmaceuticals 和 AcuteBio 宣布创新 IV 奈米乳剂Clopidogrel优化冠状动脉疾病治疗并获得 FDA IND核准
    • SERB Pharmaceuticals 和 SFJ Pharmaceuticals 宣布在美国合作开发替格瑞洛拮抗剂 Bentracimab。
    • 百时美施贵宝和杨森合作推进 FXIa 抑制剂临床试验的开发
  • 战略分析和建议
    • 辉瑞公司
    • 拜耳公司
    • Astra Zeneca
    • 赛诺菲公司

公司名单

  • Abbott Laboratories
  • Alta Laboratories Ltd.
  • Apotex Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Laboratories Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc. by F. Hoffmann-La Roche AG
  • Lupin Ltd.
  • Natco Pharma Limited
  • Otsuka Pharmaceutical Co., Ltd.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi SA
  • Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
Product Code: MRR-CA17E905E959

The Antiplatelet Market was valued at USD 3.93 billion in 2023, expected to reach USD 4.19 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 6.19 billion by 2030.

Antiplatelet drugs are essential therapeutics used to prevent platelet aggregation, thereby mitigating the risk of thrombotic events such as stroke and myocardial infarction. The necessity for such drugs is underscored by the global increase in cardiovascular diseases, driven by aging populations, dietary habits, and sedentary lifestyles. These medications find primary application in acute coronary syndrome, after percutaneous coronary intervention, and in the prevention of ischemic strokes. The end-use scope predominantly includes hospitals, clinics, and ambulatory surgical centers, signifying a strong demand in regions with advanced healthcare infrastructure as well as emerging markets experiencing rapid healthcare enhancements. Key growth factors of this market include rising cardiovascular disease burden, increased awareness and diagnosis rates, and the development of novel drugs with improved efficacy and safety profiles. There are significant opportunities linked with the introduction of personalized medicine approaches and the continued development of combination therapies, which offer enhanced clinical outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 3.93 billion
Estimated Year [2024] USD 4.19 billion
Forecast Year [2030] USD 6.19 billion
CAGR (%) 6.67%

Despite its potential, the antiplatelet market faces several limitations and challenges. Stringent regulatory requirements, potential side effects, and the high cost of advanced therapeutics can hinder market growth. Additionally, the availability of alternative therapies like anticoagulants may impact antiplatelet drug adoption. Nevertheless, innovative research areas such as the development of new drug delivery systems, and improved formulations with fewer side effects, present significant business growth opportunities. Investing in precision medicine and biotechnology for personalized treatment options can also be pivotal. Meanwhile, understanding the competitive dynamics, such as consolidation trends among pharmaceutical companies and strategic collaborations for research and development, is crucial for market penetration and expansion. A precise focus on addressing these challenges, aligning with regulatory norms, and leveraging technological advancements will be critical in navigating the future landscape of the antiplatelet market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiplatelet Market

The Antiplatelet Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing global prevalence of cardiovascular diseases
    • Supportive government investment in the pharmaceutical sector
  • Market Restraints
    • Rising incidences of the product recalls for antiplatelets
    • Side effects and risk of bleeding associated with antiplatelet
  • Market Opportunities
    • Growing trend toward personalized medicine to develop personalized antiplatelet therapies
    • Extensive research & development and clinical trials of novel antiplatelet drugs
  • Market Challenges
    • Stringent regulatory requirements and the lengthy approval process for new drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antiplatelet Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiplatelet Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiplatelet Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiplatelet Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiplatelet Market

A detailed market share analysis in the Antiplatelet Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiplatelet Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiplatelet Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiplatelet Market

A strategic analysis of the Antiplatelet Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiplatelet Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alta Laboratories Ltd., Apotex Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Bristol-Myers Squibb Company, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Genentech, Inc. by F. Hoffmann-La Roche AG, Lupin Ltd., Natco Pharma Limited, Otsuka Pharmaceutical Co., Ltd., Perrigo Company PLC, Pfizer Inc., Sanofi S.A, Shenzhen Salubris Pharmaceuticals Co., Ltd., and Sun Pharmaceutical Industries, Inc..

Market Segmentation & Coverage

This research report categorizes the Antiplatelet Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Abciximab, Aspirin, Clopidogrel, Dipyridamole, Prasugrel, Ticagrelor, Ticlopidine, and Tirofiban.
  • Based on Drug Formulation, market is studied across Capsule, Injection, and Tablet.
  • Based on Indication, market is studied across Coronary Artery Disease, Peripheral Artery Disease, and Stroke. The Stroke is further studied across Hemorrhagic and Ischemic.
  • Based on Mechanism of Action, market is studied across COX Inhibitors, P2Y12 Inhibitors, and Phosphodiesterase Inhibitors.
  • Based on Mode of Administration, market is studied across Intravenous and Oral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, Homecare Settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing global prevalence of cardiovascular diseases
      • 5.1.1.2. Supportive government investment in the pharmaceutical sector
    • 5.1.2. Restraints
      • 5.1.2.1. Rising incidences of the product recalls for antiplatelets
      • 5.1.2.2. Side effects and risk of bleeding associated with antiplatelet
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing trend toward personalized medicine to develop personalized antiplatelet therapies
      • 5.1.3.2. Extensive research & development and clinical trials of novel antiplatelet drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and the lengthy approval process for new drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Formulation: Expanding use of injection for antiplatelet usage
    • 5.2.2. Drug Type : Extensive use of Abciximab for high-risk cardiovascular interventions
    • 5.2.3. Mechanism of Action: Burgeoning utilization of COX inhibitors for inhibiting the blockages
    • 5.2.4. Indication: Growing demand for antiplatelet medications addressing the rising prevalence of cardiovascular diseases
    • 5.2.5. Mode of Administration: Proliferating use of oral routes for administration of antiplatelets
    • 5.2.6. End User : Growing need of antiplatelet medications in ambulatory surgical centers
    • 5.2.7. Distribution Channel : Extensive use of hospital pharmacies owing to their direct access to patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antiplatelet Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Abciximab
  • 6.3. Aspirin
  • 6.4. Clopidogrel
  • 6.5. Dipyridamole
  • 6.6. Prasugrel
  • 6.7. Ticagrelor
  • 6.8. Ticlopidine
  • 6.9. Tirofiban

7. Antiplatelet Market, by Drug Formulation

  • 7.1. Introduction
  • 7.2. Capsule
  • 7.3. Injection
  • 7.4. Tablet

8. Antiplatelet Market, by Indication

  • 8.1. Introduction
  • 8.2. Coronary Artery Disease
  • 8.3. Peripheral Artery Disease
  • 8.4. Stroke
    • 8.4.1. Hemorrhagic
    • 8.4.2. Ischemic

9. Antiplatelet Market, by Mechanism of Action

  • 9.1. Introduction
  • 9.2. COX Inhibitors
  • 9.3. P2Y12 Inhibitors
  • 9.4. Phosphodiesterase Inhibitors

10. Antiplatelet Market, by Mode of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral

11. Antiplatelet Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Antiplatelet Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Clinics
  • 12.4. Homecare Settings
  • 12.5. Hospitals

13. Americas Antiplatelet Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Antiplatelet Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Antiplatelet Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Diapin Therapeutics advances innovative antiplatelet therapy DT678 with FDA feedback
    • 16.3.2. FDA fast-tracks approval of bentracimab as the first breakthrough solution for ticagrelor reversal
    • 16.3.3. Eugia US recalled 15 500 single-dose vials of eptifibatide injection
    • 16.3.4. Avenacy enters U.S. market with launch of generic eptifibatide injection, targeting ACS and PCI treatment
    • 16.3.5. UCHealth pioneers genetic screening for Clopidogrel to enhance heart health outcomes and revolutionize personalized medicine
    • 16.3.6. Ascendia Pharmaceuticals and AcuteBio unveil innovative IV nanoemulsion clopidogrel to optimize coronary artery disease treatment with FDA IND approval
    • 16.3.7. SERB Pharmaceuticals and SFJ Pharmaceuticals announced a U.S. partnership for bentracimab, a ticagrelor reversal agent
    • 16.3.8. Bristol Myers Squibb-Janssen collaboration advances FXIa inhibitors with clinical trials
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. Pfizer Inc.
    • 16.4.2. Bayer AG
    • 16.4.3. AstraZeneca PLC
    • 16.4.4. Sanofi S.A

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alta Laboratories Ltd.
  • 3. Apotex Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol Laboratories Ltd.
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. Daiichi Sankyo Company, Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Genentech, Inc. by F. Hoffmann-La Roche AG
  • 13. Lupin Ltd.
  • 14. Natco Pharma Limited
  • 15. Otsuka Pharmaceutical Co., Ltd.
  • 16. Perrigo Company PLC
  • 17. Pfizer Inc.
  • 18. Sanofi S.A
  • 19. Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • 20. Sun Pharmaceutical Industries, Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIPLATELET MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIPLATELET MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIPLATELET MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPLATELET MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIPLATELET MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIPLATELET MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIPLATELET MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTIPLATELET MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTIPLATELET MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTIPLATELET MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ANTIPLATELET MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ANTIPLATELET MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIPLATELET MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIPLATELET MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPLATELET MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIPLATELET MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPLATELET MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPLATELET MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPLATELET MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPLATELET MARKET SIZE, BY DIPYRIDAMOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPLATELET MARKET SIZE, BY PRASUGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPLATELET MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPLATELET MARKET SIZE, BY TICLOPIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPLATELET MARKET SIZE, BY TIROFIBAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPLATELET MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPLATELET MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPLATELET MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPLATELET MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPLATELET MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPLATELET MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPLATELET MARKET SIZE, BY HEMORRHAGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPLATELET MARKET SIZE, BY ISCHEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPLATELET MARKET SIZE, BY COX INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPLATELET MARKET SIZE, BY P2Y12 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPLATELET MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPLATELET MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPLATELET MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPLATELET MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPLATELET MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPLATELET MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPLATELET MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPLATELET MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPLATELET MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPLATELET MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES ANTIPLATELET MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 341. SWEDEN ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 357. TURKEY ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 358. TURKEY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY STROKE, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM ANTIPLATELET MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 369.